International: +1-347-960-6455
Akt/Protein Kinase B (PKB) Inhibitors - Pipeline Analysis 2018

Akt/Protein Kinase B (PKB) Inhibitors - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10154 Published: January 2019 Pages: 113 Available format: 
Therapeutic Area(s): Oncology | Metabolic | Cardiovascular | Ophthalmology | Nephrology | Neurology | Urology | Others Report Type: Mechanism of Action Reports
Select License Type
Note: This report can also be updated as of date and delivered within 1-2 working days of purchase confirmation


Akt, also known as PKB, is generally activated in several types of cancers such as breast, gastric, lung, ovary, and pancreatic cancer. Akt inhibitor prevent the functioning of activated form of Akt kinases. Akt kinases are also involved in promoting growth factor-mediated cells that mediates cell proliferation and inhibition of apoptosis through the inactivation of pro-apoptotic proteins, such as mouse double minute 2 homolog (MDM2) and Bcl-2 antagonist of cell death.

Majority of drug candidates in the Akt/Protein Kinase B (PKB) inhibitors pipeline are being developed through the advanced technologies, which enable targeted delivery of drugs or protect drugs from degradation in the body before reaching to the target. Leveraging these technologies, companies are developing biological and synthetic drugs to prevent the progression of various chronic diseases. For instance, Pyramid Discovery platform by Astex Pharmaceuticals, develops high-quality therapeutics for the treatment of a wide range of diseases.

In addition, positive clinical trial results and rise in the number of patent approvals are also facilitating drug development in this pipeline. The patent approvals help in achieving different milestones in the form of grants and designations from the regulatory bodies and institutes including the U.S. Food and Drug Administration (USFDA), the European Medicines Agency (EMA), and the National Institutes of Health (NIH) among others.

Pipeline Analysis

As of January 2019, the Akt/PKB inhibitors pipeline comprises of 23 therapeutic candidates in different stages of development.

Competitive Landscape

Some of the key players involved in the development of Akt/PKB inhibitors include F. Hoffman-La-Roche Ltd, Eli Lilly & Company, Merck & Co. Inc., Novartis AG, Denovo Biopharma LLC, Diffusion Pharmaceuticals Inc., Astex Pharmaceuticals, ArQule Inc., Cotinga Pharmaceuticals Inc., and Oneness Biotech Co. Ltd.